HIV/AIDS, April 14 -- Today's announcement that US pharmaceutical corporation Gilead Sciences will be supplying the highly effective HIV prevention medication lenacapavir to one million more people in a limited number of low- and middle-income countries (LMICs) does not address the fundamental barriers keeping people from accessing this medicine, Doctors Without Borders/Medecins Sans Frontieres (MSF) said today.

Gilead had previously announced that it would be supplying doses to two million people, bringing the total to three million in three years. This is not nearly enough to meet the global need, and excludes people in some of the places where HIV is most prevalent.

Approximately 1.3 million people worldwide acquire HIV every year, i...